Luminex Delivers xMAP® INTELLIFLEX Systems to Life Science Research Partners

Luminex Delivers xMAP® INTELLIFLEX Systems to Life Science Research Partners


AUSTIN, Texas, July 1, 2020 /PRNewswire/ — Luminex Company (NASDAQ: LMNX) immediately introduced that the corporate has delivered the primary of its new xMAP® INTELLIFLEX Methods to a number of of its Life Science Analysis Companions, attaining a serious milestone within the firm’s technique to increase its xMAP Know-how with new performance to facilitate new purposes. Initially supposed for analysis use solely, the brand new system can double the multiplex capabilities of the xMAP platform, enabling companions and prospects to discover new purposes. Included in these purposes is the distinctive means to make use of a dual-reporter to concurrently detect a number of COVID-19 antibodies in a single serology check.

The brand new xMAP INTELLIFLEX System is a contemporary, compact and sturdy model of the confirmed xMAP platform, absolutely appropriate with the prevailing xMAP assay menu. It represents the following step in enhanced options and performance on the xMAP platform, which is taken into account the trade’s gold normal for multiplexing of organic exams. Greater than 17,000 xMAP techniques have been offered globally for multiplex evaluation, with greater than 50,000 peer-reviewed publications, and 65+ international companions providing 1,300+ kits and customized assay options on the platform.

“We’re very excited to carry this next-generation xMAP System to our companions. This marks one other main milestone for Luminex that coincides with the 25th anniversary of the founding of our firm and our modern management within the multiplex testing market,” mentioned Nachum “Homi” Shamir, President and CEO of Luminex. “The expanded performance of the brand new xMAP INTELLIFLEX System will allow our companions to develop novel, high-value assays that aren’t doable on current techniques available in the market, which is especially vital as we work collectively to deal with this international pandemic. As soon as once more, Luminex expertise will drive a brand new wave of development in analysis.”

The twin-reporter, a brand new key function within the INTELLIFLEX system, can empower prospects to double their multiplex capabilities, which allows them to acquire extra information with much less pattern, whereas additionally optimizing their workflow. Different xMAP INTELLIFLEX options embrace new touchscreen controls, an improved person interface, a streamlined setup, and higher workflow management as a consequence of enhanced software program. The instrument additionally has improved optics and fluidics, enabling assay designers to discover the event of extra delicate and sturdy xMAP assays.

As a part of the phased rollout of the brand new INTELLIFLEX resolution, Luminex will likely be transport further items to main analysis establishments and different companions throughout Q3. The corporate plans to completely commercialize the xMAP INTELLIFLEX System by the tip of the yr.

About xMAP Know-how

A well-established platform for multiplex evaluation with greater than 50,000 peer-reviewed publications, 65+ Luminex international companions providing 1,300+ kits and customized assay options, xMAP Know-how makes use of a bead-based multiplexing assay strategy that may quickly detect and quantify a number of analytes in a single pattern. Multiplex serological testing can concurrently analyze giant numbers of antigens for large-scale screening and has the potential to interchange ELISA assays. Serological assays on the xMAP platform cut back time to outcomes, reduce the amount of pattern wanted, and speed up the testing course of with out the necessity for extra labor, demonstrating developments over ELISA assays for antibody testing. Extra details about xMAP Know-how is on the market at https://www.luminexcorp.com/xmap-technology/.

About Luminex Company

At Luminex, our mission is to empower labs to acquire dependable, well timed, and actionable solutions, in the end advancing well being. We provide a variety of options relevant in various markets together with medical diagnostics, pharmaceutical drug discovery, biomedical analysis, genomic and proteomic analysis, biodefense analysis, and meals security. We speed up dependable solutions whereas simplifying complexity and ship certainty with a seamless expertise. To be taught extra about Luminex, please go to us at luminexcorp.com.

Cautionary Assertion Relating to Ahead-Wanting Statements

This press launch comprises forward-looking statements regarding Luminex’s enterprise outlook, the launch of a particular product line, in addition to different statements that confer with future plans and expectations, together with across the growth of merchandise which have a job in addressing the novel coronavirus. Such statements contain a variety of dangers and uncertainties. Phrases reminiscent of “can,” “plans,” “will,” “speed up,” “facilitate,” “allow,” “supposed,” “develop” and variations of such phrases and related expressions are supposed to establish forward-looking statements. Statements that confer with or are primarily based on estimates, forecasts, projections, unsure occasions or assumptions, and anticipated traits in our companies or the markets related to them, additionally establish forward-looking statements. Such statements are primarily based on administration’s expectations as of the date they have been first made and, besides as required by legislation, Luminex disclaims any obligation to replace these statements to replicate future occasions or circumstances. Ahead-looking statements contain many dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied in such statements. Necessary components that would trigger precise outcomes to vary materially from the corporate’s expectations embrace modifications in market situations, provide constraints and different disruptions, modifications in capital necessities, and different components set forth in Luminex’s most up-to-date Annual Report on Type 10-Ok filed with the SEC and obtainable at Luminex’s web site at www.luminexcorp.com and the SEC’s web site at sec.gov.

Investor Contacts:
Harriss Currie
Sr. Vice President of Finance and CFO
[email protected]
512-219-8020

Media Contact:
Michele Parisi
Bioscribe
[email protected]
925-864-5028

SOURCE Luminex Company

Associated Hyperlinks

http://www.luminexcorp.com



credit score :Source link

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *